Skip to main content
TipRanks
Go Ultimate75% OFF

Lexicon Pharmaceuticals (LX31) AI Stock Analysis

5 Followers
DE:LX31

Lexicon Pharmaceuticals

(Dusseldorf:LX31)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetA debt-free balance sheet gives Lexicon greater financial flexibility while its pipeline advances through clinical and regulatory milestones. The absence of reported debt reduces refinancing and interest burdens, allowing more resources to remain available for research, development, and pre-commercial preparation.
Negative Factors
Persistent operating lossesDeep operating and net losses show that Lexicon has not yet converted its development portfolio into a self-sustaining earnings model. Even with losses narrowing versus 2024, continued negative profitability can constrain reinvestment capacity and leave future progress dependent on financing, milestones, or commercialization.

Lexicon Pharmaceuticals (LX31) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:LX31-20.40%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 796.97M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-12.3
Beta (1Y)
1.44
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
81
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Lexicon Pharmaceuticals Business Overview & Revenue Model

Company Description

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug...

Lexicon Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with management highlighting completed SONATA-HCM enrollment, encouraging STENO1 safety data, the planned ZYNQUISTA NDA resubmission, regulatory progress through Viatris, a $10 million LX9851 milestone, promising pilavapadin weight-loss data, and a higher cash balance. The principal negatives were lower year-over-year revenue, a larger net loss, higher SG&A expenses, and delays and administrative complexity surrounding the ZYNQUISTA resubmission. Multiple significant clinical and regulatory catalysts expected in the first quarter of 2027 supported an overall favorable tone.

Positive Updates

SONATA-HCM Enrollment Completed
Lexicon completed enrollment in the phase III SONATA-HCM study, which included 542 patients: 440 with non-obstructive HCM and 102 with obstructive HCM. The study population had a mean baseline KCCQ score of 59, reflecting a highly symptomatic population, and top-line results are expected in the first quarter of 2027.

Negative Updates

Revenue Declined Year Over Year
Third-quarter 2026 revenue was $11.3 million, compared with $14.2 million in the corresponding period of 2025, a decrease of approximately 20%. The prior-year quarter included $13.2 million of Novo Nordisk licensing revenue, compared with $10 million of milestone revenue in the third quarter of 2026.

Company Guidance

Lexicon maintained its 2026 operating expense guidance of between $100 million and $110 million, with R&D expected to be between $63 million and $68 million and SG&A expected to be between $37 million and $42 million; the company expects SONATA-HCM top-line results in the first quarter of 2027, expects to complete the ZYNQUISTA NDA resubmission in the first quarter of 2027, expects SOTA-CROSS completion in 2027, and expects additional milestone payments as LX9851 advances.

Lexicon Pharmaceuticals Risk Analysis

Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Lexicon Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:LX31 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RIGLRIGL69Neutral$837.18M2.6473.94%―2.18%165.65%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RGNXRGNX51Neutral$505.18M-2.38-203.98%―-4.59%8.03%
BCYCBCYC45Neutral$235.88M-1.66-26.02%―194.79%43.93%
PRTAPRTA42Neutral$419.01M-17.36-8.34%―347.44%91.00%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%DE:LX31RIGLPRTARGNXBCYCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:LX31 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:LX31Lexicon Pharmaceuticals1.01-0.24-19.18%
RIGLRigel Pharmaceuticals44.461.954.59%
PRTAProthena Corporation8.16-2.09-20.39%
RGNXRegenXBio Inc.7.64-3.50-31.42%
BCYCBicycle Therapeutics3.37-3.09-47.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.